检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial.

Shoji Nagao,Keiichi Fujiwara,Kouji Yamamoto,Hiroshi Tanabe,Aikou Okamoto,Kazuhiro Takehara, Motoaki Saito,Hiroyuki Fujiwara,David S P Tan,Satoshi Yamaguchi,Sosuke Adachi,Akira Kikuchi,Takeshi Hirasawa,Takeshi Yokoi,Tomonori Nagai,Toyomi Sato,Shoji Kamiura,Akira Fujishita, Wong Wai Loong,Karen Chan, Peter Syks, Alexsander Olawaye,Sang-Young Ryu,Hiroyuki Shigeta,Eiji Kondo,Yoshihito Yokoyama,Takashi Matsumoto,Kosei Hasegawa,Takayuki Enomoto

NEJM evidence（2023）

引用 0|浏览7
暂无评分
摘要
Intraperitoneal Carboplatin for Ovarian CancerThis trial compared intravenous weekly paclitaxel administered with intraperitoneal or intravenous carboplatin. There was a statistically significant increase in progression-free survival in patients with ovarian cancer treated with intraperitoneal versus intravenous carboplatin and paclitaxel, with no difference in overall survival between groups.
更多
查看译文
关键词
intraperitoneal carboplatin,ovarian cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要